Literature DB >> 18820670

Multiple genes are hypermethylated in intraductal papillary mucinous neoplasms of the pancreas.

Seung-Mo Hong1, David Kelly, Margaret Griffith, Noriyuki Omura, Ang Li, Chung-Pin Li, Ralph H Hruban, Michael Goggins.   

Abstract

Ductal adenocarcinoma of the pancreas is the fourth leading cause of cancer death and is usually diagnosed late. Intraductal papillary mucinous neoplasms are an increasingly recognized precursor to invasive ductal adenocarcinoma of the pancreas. Identifying the alterations in DNA methylation that arise during intraductal papillary mucinous neoplasm development may facilitate the development of markers that could be used to differentiate intraductal papillary mucinous neoplasms from non-neoplastic pancreatic cystic lesions. Surgically resected intraductal papillary mucinous neoplasms and adjacent ductal adenocarcinomas were microdissected from 50 patients. Normal pancreas was also obtained from 27 patients with intraductal papillary mucinous neoplasms or pancreatic adenocarcinomas and 10 patients with well-differentiated pancreatic endocrine neoplasms. Methylation-specific PCR was performed on isolated DNA for seven genes (SPARC, SARP2, TSLC1, RELN, TFPI2, CLDN5, UCHL1) known to be commonly aberrantly methylated in pancreatic ductal adenocarcinomas. The mean percentage of genes methylated in invasive ductal adenocarcinomas arising in association with an intraductal papillary mucinous neoplasm (mean+/-s.d., 81+/-17%) was significantly higher than that in noninvasive-intraductal papillary mucinous neoplasms (57+/-26%, P=0.007) or peritumoral normal epithelial cells (22+/-17%, P<0.0001). Carcinomas (intraductal papillary mucinous neoplasms with carcinoma in situ or their associated infiltrating adenocarcinoma) had significantly more methylated genes (71+/-19%) than low-grade (low and moderate dysplasia) intraductal papillary mucinous neoplasms (44+/-26%, P<0.0001). The mean percentage of genes methylated in histologically normal pancreatic ductal cells from patients with ductal neoplasia (22+/-17%) was significantly higher than in normal ductal cells from patients with well-differentiated pancreatic endocrine neoplasms (4+/-7%, P=0.002). Thus, aberrant DNA methylation increases with histologic grades of intraductal papillary mucinous neoplasm. Low-level aberrant methylation in the normal ductal cells is more prevalent in patients with ductal neoplasia than in controls without ductal neoplasms and may contribute to carcinogenesis. The detection of aberrant methylation in pancreatic cystic lesions could facilitate the diagnosis of intraductal papillary mucinous neoplasms.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18820670      PMCID: PMC2678809          DOI: 10.1038/modpathol.2008.157

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  42 in total

1.  Study of recurrence after surgical resection of intraductal papillary mucinous neoplasm of the pancreas.

Authors:  Suresh T Chari; Dhiraj Yadav; Thomas C Smyrk; Eugene P DiMagno; Laurence J Miller; Massimo Raimondo; Jonathan E Clain; Ian A Norton; Randall K Pearson; Bret T Petersen; Maurits J Wiersema; Michael B Farnell; Michael G Sarr
Journal:  Gastroenterology       Date:  2002-11       Impact factor: 22.682

2.  Diagnosing pancreatic cancer using methylation specific PCR analysis of pancreatic juice.

Authors:  Noriyoshi Fukushima; Kimberly M Walter; Takashi Uek; Norihiro Sato; Hiroyuki Matsubayashi; John L Cameron; Ralph H Hruban; Marcia Canto; Charles J Yeo; Michael Goggins
Journal:  Cancer Biol Ther       Date:  2003 Jan-Feb       Impact factor: 4.742

3.  Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas.

Authors:  Benoit Terris; Ekaterina Blaveri; Tatjana Crnogorac-Jurcevic; Melanie Jones; Edoardo Missiaglia; Philippe Ruszniewski; Alain Sauvanet; Nicholas R Lemoine
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

4.  STK11/LKB1 Peutz-Jeghers gene inactivation in intraductal papillary-mucinous neoplasms of the pancreas.

Authors:  N Sato; C Rosty; M Jansen; N Fukushima; T Ueki; C J Yeo; J L Cameron; C A Iacobuzio-Donahue; R H Hruban; M Goggins
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

5.  Aberrant methylation of the 5' CpG island of TSLC1 is common in pancreatic ductal adenocarcinoma and is first manifest in high-grade PanlNs.

Authors:  Marnix Jansen; Noriyoshi Fukushima; Christophe Rosty; Kim Walter; Renee Altink; Tjarda Van Heek; Ralph Hruban; Johan G Offerhaus; Michael Goggins
Journal:  Cancer Biol Ther       Date:  2002 May-Jun       Impact factor: 4.742

6.  Molecular progression of promoter methylation in intraductal papillary mucinous neoplasms (IPMN) of the pancreas.

Authors:  Michael G House; MingZhou Guo; Christine Iacobuzio-Donahue; James G Herman
Journal:  Carcinogenesis       Date:  2003-02       Impact factor: 4.944

7.  Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression.

Authors:  R E Wilentz; C A Iacobuzio-Donahue; P Argani; D M McCarthy; J L Parsons; C J Yeo; S E Kern; R H Hruban
Journal:  Cancer Res       Date:  2000-04-01       Impact factor: 12.701

8.  Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays.

Authors:  Norihiro Sato; Noriyoshi Fukushima; Anirban Maitra; Hiroyuki Matsubayashi; Charles J Yeo; John L Cameron; Ralph H Hruban; Michael Goggins
Journal:  Cancer Res       Date:  2003-07-01       Impact factor: 12.701

9.  Aberrant methylation of CpG islands in intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Norihiro Sato; Takashi Ueki; Noriyoshi Fukushima; Christine A Iacobuzio-Donahue; Charles J Yeo; John L Cameron; Ralph H Hruban; Michael Goggins
Journal:  Gastroenterology       Date:  2002-07       Impact factor: 22.682

10.  Differential and epigenetic gene expression profiling identifies frequent disruption of the RELN pathway in pancreatic cancers.

Authors:  Norihiro Sato; Noriyoshi Fukushima; Rubens Chang; Hiroyuki Matsubayashi; Michael Goggins
Journal:  Gastroenterology       Date:  2006-02       Impact factor: 22.682

View more
  37 in total

Review 1.  Molecular signatures of pancreatic cancer.

Authors:  Seung-Mo Hong; Jason Y Park; Ralph H Hruban; Michael Goggins
Journal:  Arch Pathol Lab Med       Date:  2011-06       Impact factor: 5.534

2.  Matricellular proteins osteopontin and osteonectin/SPARC in pancreatic carcinoma.

Authors:  Anne M Delany
Journal:  Cancer Biol Ther       Date:  2010-07-01       Impact factor: 4.742

3.  Pancreatic cancer DNMT1 expression and sensitivity to DNMT1 inhibitors.

Authors:  Ang Li; Noriyuki Omura; Seung-Mo Hong; Michael Goggins
Journal:  Cancer Biol Ther       Date:  2010-02-01       Impact factor: 4.742

4.  Predicting the Grade of Dysplasia of Pancreatic Cystic Neoplasms Using Cyst Fluid DNA Methylation Markers.

Authors:  Tatsuo Hata; Marco Dal Molin; Seung-Mo Hong; Koji Tamura; Masaya Suenaga; Jun Yu; Hiraku Sedogawa; Matthew J Weiss; Christopher L Wolfgang; Anne Marie Lennon; Ralph H Hruban; Michael G Goggins
Journal:  Clin Cancer Res       Date:  2017-02-01       Impact factor: 12.531

5.  Loss of expression of the SWI/SNF chromatin remodeling subunit BRG1/SMARCA4 is frequently observed in intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Marco Dal Molin; Seung-Mo Hong; Sachidanand Hebbar; Rajni Sharma; Francesca Scrimieri; Roeland F de Wilde; Skye C Mayo; Michael Goggins; Christopher L Wolfgang; Richard D Schulick; Ming-Tseh Lin; James R Eshleman; Ralph H Hruban; Anirban Maitra; Hanno Matthaei
Journal:  Hum Pathol       Date:  2011-09-21       Impact factor: 3.466

6.  Genome-wide analysis of promoter methylation associated with gene expression profile in pancreatic adenocarcinoma.

Authors:  Audrey Vincent; Noriyuki Omura; Seung-Mo Hong; Andrew Jaffe; James Eshleman; Michael Goggins
Journal:  Clin Cancer Res       Date:  2011-05-24       Impact factor: 12.531

7.  MicroRNA alterations of pancreatic intraepithelial neoplasias.

Authors:  Jun Yu; Ang Li; Seung-Mo Hong; Ralph H Hruban; Michael Goggins
Journal:  Clin Cancer Res       Date:  2011-11-23       Impact factor: 12.531

8.  Lack of host SPARC enhances vascular function and tumor spread in an orthotopic murine model of pancreatic carcinoma.

Authors:  Shanna A Arnold; Lee B Rivera; Andrew F Miller; Juliet G Carbon; Sean P Dineen; Yang Xie; Diego H Castrillon; E Helene Sage; Pauli Puolakkainen; Amy D Bradshaw; Rolf A Brekken
Journal:  Dis Model Mech       Date:  2009-12-09       Impact factor: 5.758

9.  APC promoter is frequently methylated in pancreatic juice of patients with pancreatic carcinomas or periampullary tumors.

Authors:  Mireia M Ginesta; Zamira Vanessa Diaz-Riascos; Juli Busquets; Núria Pelaez; Teresa Serrano; Miquel Àngel Peinado; Rosa Jorba; Francisco Javier García-Borobia; Gabriel Capella; Joan Fabregat
Journal:  Oncol Lett       Date:  2016-07-15       Impact factor: 2.967

10.  SPARC: a matricellular regulator of tumorigenesis.

Authors:  Shanna A Arnold; Rolf A Brekken
Journal:  J Cell Commun Signal       Date:  2009-10-07       Impact factor: 5.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.